NasdaqHealth CareHealth Care TechnologyS&P SmallCap 600
$37.34
-0.69 (-1.81%)
Close of Nov 06, 2026 · end-of-day data
OMCL 8-K filings in 2026
Every material Form 8-K Omnicell filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Omnicell reported third-quarter 2026 revenue of $308 million, down $3 million, or 1%, from a year earlier, while GAAP net income rose to $11 million, or $0.24 per diluted share, from $5 million, or $0.12. The company raised its full-year 2026 non-GAAP EBITDA and non-GAAP earnings per share guidance, so profit expectations improved even as revenue slipped.
Q3 2026 non-GAAP net income was $27 million, or $0.58 per diluted share, versus $24 million, or $0.51, in Q3 2025.
Full-year 2026 non-GAAP EBITDA guidance was raised to $187 million-$193 million; non-GAAP EPS guidance was raised to $2.48-$2.56.
Full-year 2026 total revenue guidance was tightened to $1.225 billion-$1.231 billion.
As of September 30, 2026, cash and cash equivalents were $315 million and the company had $350 million of undrawn revolving credit availability.
Omnicell reported second quarter 2026 revenue of $312 million, up 7% from a year earlier, and GAAP net income of $24 million, or $0.52 per diluted share, versus $6 million a year earlier. The company raised its full-year 2026 non-GAAP EBITDA and non-GAAP EPS guidance, and narrowed its full-year revenue range to $1.225 billion to $1.245 billion. Results include a $15 million refund of previously paid IEEPA tariffs.
Q2 2026 non-GAAP EPS was $0.94, up from $0.45; non-GAAP EBITDA was $67 million, up from $38 million
Full-year 2026 guidance: non-GAAP EBITDA $175 million to $185 million; non-GAAP EPS $2.15 to $2.30
Q3 2026 total revenue guidance is $301 million to $307 million; full-year product bookings guidance is $425 million to $560 million
On July 1, 2026, Nnamdi Njoku was named President and Chief Operating Officer
Omnicell appointed Nnamdi Njoku as President effective July 1, 2026, while he keeps his role as Chief Operating Officer. Randall Lipps stepped down as President but continues as Chief Executive Officer and Chairman, and Njoku will report to him. The filing describes this as a change in how Omnicell's top leadership duties are divided, with Njoku focused on long-term growth strategy and operational execution.
Njoku was appointed President effective July 1, 2026, and remains Chief Operating Officer; he had been COO since October 2024
Lipps stepped down as President; he remains CEO and Chairman with no compensation changes tied to the transition
Board approved a one-time restricted stock unit award with a target grant date value of approximately $500,000; one-third vests after one year, the rest in equal amounts at two and three years
Njoku's 2026 base salary is unchanged at $661,000, with a target cash bonus of 100% of base salary
At its May 19, 2026 annual meeting, Omnicell stockholders elected Joanne B. Bauer, Robin G. Seim and Eileen J. Voynick as Class I directors and approved an amendment adding 1,600,000 shares to the 2009 Equity Incentive Plan. They also approved a charter amendment, filed May 20, 2026, that provides officer exculpation from personal liability as permitted by Delaware law, and ratified Deloitte & Touche LLP as auditor for 2026. The share increase expands the number of shares available for issuance under the plan.
Bauer, Seim and Voynick elected to serve until the 2029 Annual Meeting of Stockholders
Equity plan amendment approved: 35,182,712 for, 1,472,716 against, 100,392 abstain, 4,704,566 broker non-votes
Charter amendment approved: 34,320,796 for, 2,419,140 against, 15,884 abstain; filed with Delaware on May 20, 2026
Deloitte & Touche LLP ratified for the year ending December 31, 2026: 41,224,274 for, 206,940 against
Omnicell reported first-quarter 2026 total revenue of $310 million, up 15% from a year earlier, and GAAP net income of $11 million, or $0.25 per diluted share, compared with a net loss of $7 million, or $0.15 per share, in the first quarter of 2025. The company raised its full-year 2026 non-GAAP EBITDA and non-GAAP earnings per share guidance, citing first-quarter profitability and spend discipline.
Total revenue of $310 million, up $40 million, or 15%, from the first quarter of 2025.
GAAP net income of $11 million ($0.25 per diluted share) versus a GAAP net loss of $7 million ($0.15 per share) a year earlier.
Full-year 2026 non-GAAP EBITDA guidance raised to $153 million-$168 million; non-GAAP EPS guidance raised to $1.80-$2.00.
Cash and cash equivalents of $239 million as of March 31, 2026; second-quarter 2026 total revenue guidance of $307 million-$313 million.
Omnicell reported fourth quarter and full-year 2025 results on February 5, 2026. Revenue grew, with full-year revenue of $1.185 billion up 7%, but profit fell: full-year GAAP net income dropped to $2 million from $13 million, and the fourth quarter posted a GAAP net loss. The company also guided 2026 total revenues to $1.215 billion to $1.255 billion and non-GAAP earnings per share to $1.65 to $1.85.
Q4 2025 revenue was $314 million, up $7 million or 2%; GAAP net loss was $2 million ($0.05 per diluted share) versus GAAP net income of $16 million ($0.34) in Q4 2024.
Full-year 2025 revenue was $1.185 billion, up 7%; GAAP net income was $2 million ($0.04 per diluted share) versus $13 million in 2024.
Full-year 2025 non-GAAP earnings per diluted share were $1.62, down from $1.71; product bookings were $535 million, down 4% from $558 million.
2026 guidance: total revenues of $1.215 billion to $1.255 billion, non-GAAP EBITDA of $145 million to $160 million, and non-GAAP EPS of $1.65 to $1.85.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Omnicell filing is on SEC EDGAR ↗. 8-K briefs of other companies →